New review consolidates research on Novonesis’ BB-12 probiotic strain for digestion and infant health
An extensive peer-reviewed review gathers decades of research into Novonesis’ BB-12 (Bifidobacterium animalis subsp. lactis), one of the most thoroughly researched probiotic strains. It offers a singular, accessible resource encompassing the strain’s mechanisms of action, clinical efficacy, and its relevance across all stages of life.
The review details the BB-12 strain’s various attributes, including its survival in the gastrointestinal tract, bile salt tolerance and metabolic activity, adherence to intestinal epithelial cells, immune modulation, and its impact on gut microbiota and short-chain fatty acid production. It also covers its clinical efficacy in constipation and infant colic.
As the demand for scientifically validated probiotics grows, navigating the fragmented evidence can be difficult, notes Novonesis. The new review on the BB-12 strain aims to provide clarity and credibility.
“It’s very exciting that we’re able to share this with our customers now,” says Linda Neckmar, SVP of Human Health at Novonesis. “We’ve known about the many benefits of the BB-12 strain for a long time, but this comprehensive review is a powerful tool for anyone working with it. It helps our partners communicate on health benefits with confidence, backed by science.”
Consolidating a mass of evidence
The review addresses the pervasive challenges associated with digestive health, from irregular bowel movements to disruptions in immune regulation, which impact millions globally.
It compiles an extensive body of evidence from over 400 publications and 200 clinical studies on the BB-12 probiotic strain. Novonesis calls it a “one-stop reference for formulators, healthcare professionals, and brand owners.”
“This review is a milestone,” says Neckmar. “It gives our partners and customers a complete picture of how the BB-12 strain works and why it’s trusted globally.”
BB-12 strain’s role spans from immune function and regular bowel movements to addressing colic in infants.Beyond gut health, the review also delves into the BB-12 strain’s role spanning from immune function and regular bowel movements to addressing excessive crying and fussing in infants, underscoring its applicability across all life stages.
The review specifically highlights the BB-12 strain’s proven ability to survive the harsh conditions of the gastrointestinal tract, including acidic pH and bile salts, with clinical studies demonstrating its live transit.
While its colonization is transient, the BB-12 strain can interact with host epithelial and immune cells, leading to improved barrier function and modulated immune responses. It enhances antibody IgA secretion, reduces inflammation, and promotes beneficial metabolic activity in the gut microbiota, including increased short-chain fatty acid production.
Moreover, the review identifies avenues for further research into the BB-12 strain’s mechanisms and potential new health applications.
“This is not just a literature summary. It’s a rigorous, peer-reviewed manuscript that validates the BB-12 strain’s mechanisms of action and clinical outcomes. And while this review brings together decades of research, it also opens the door to future discovery,” says Martin Kullen, VP of Human Health Science & Innovation at Novonesis.
“As we continue to learn more about the microbiome and its role in human health, the BB-12 strain remains a cornerstone for innovation and exploration.”
The review is featured in a special issue of the journal Frontiers in Microbiology.
